Lipitor and protein creation what's the connection?

Lipitor lowers cholesterol by blocking an enzyme in the liver that produces cholesterol.

What happens to cholesterol synthesis when Lipitor binds HMG-CoA reductase?

Lipitor inhibits HMG-CoA reductase, the rate-limiting step in the mevalonate pathway. When this enzyme is blocked, liver cells sense lower cholesterol levels and activate SREBP-2 transcription factors. SREBP-2 then increases expression of LDL receptors on the cell surface, pulling LDL particles from the blood into the liver for processing.

Does Lipitor affect protein synthesis directly?

Lipitor does not interact with ribosomes or amino acid tRNA charging. It targets only the enzyme HMG-CoA reductase. Any observed changes in protein levels come from secondary effects, such longer-lasting LDL receptors or altered isoprenoid-dependent signaling that can influence gene expression.

What happens if cholesterol synthesis is reduced long-term?

Reduced cholesterol synthesis means fewer isoprenoids, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These molecules attach to proteins through prenylation, a post-translational modification that helps proteins anchor to membranes. Prenylated proteins include Ras, Rho, and Cdc42, which control cell signaling and movement. Long-term inhibition of the mevalonate pathway can therefore affect signaling proteins that already exist rather than stopping new protein creation.

When does the patent for Lipitor expire?

The primary compound patent expired in 2011. DrugPatentWatch.com lists subsequent formulation and polymorph patents that are still active, protecting some generic versions from entering fully.